RE:RE:RE:What?Actually if you look at some of the earlier cohorts there are a few IRs that went to CR, briefly, or NRs that went to CR, briefly...
My take is TLT has got the science correct for NMIBC, it is the art where they need more work. We have a patient population here that is fragile, may have other health issues. Different bladder shapes/sizes. Perhaps some simply can't pass the 'can you hold it that long?' test....
When it comes to less complex dosimetry, drug delivery, like maybe topical skin cancers or solid tumors, Ruvidar should achieve very good or excellent CR+IR percentages. IMO